Plinabulin Clinical Development Program
Our lead drug candidate Plinabulin, is in late phase development in patients with advanced non-small cell lung cancer (NSCLC). Early exploratory clinical trials are under consideration for several other indications, supported by non-clinical projects in cancer genomics and discovery biology.
In NSCLC, Phase 1 and 2 trials have been completed. Currently, we are evaluating Plinabulin in an ongoing Phase 3 pivotal study for global registration, started Q3 2015. Learn more about our unique approach to delivering optimal results and the pivotal Phase 3 NSCLC trial.